Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.26 Million USD | -19.44% |
| 2022 | 1.56 Million USD | 5293.1% |
| 2021 | 29 Thousand USD | -91.92% |
| 2020 | 359 Thousand USD | -45.77% |
| 2019 | 662 Thousand USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 3.45 Million USD | 5.53% |
| 2016 | 3.26 Million USD | 51.96% |
| 2015 | 2.15 Million USD | 37.18% |
| 2014 | 1.56 Million USD | 462.66% |
| 2013 | 278.74 Thousand USD | 552.04% |
| 2012 | 42.75 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 1.23 Million USD | 12.27% |
| 2024 Q2 | 1.1 Million USD | -6.86% |
| 2024 Q1 | 1.18 Million USD | -6.27% |
| 2023 Q1 | 1.49 Million USD | -4.73% |
| 2023 Q3 | 1.33 Million USD | -5.45% |
| 2023 Q2 | 1.41 Million USD | -5.1% |
| 2023 Q4 | 1.26 Million USD | -5.76% |
| 2023 FY | 1.26 Million USD | -19.44% |
| 2022 Q2 | 1.65 Million USD | 0.73% |
| 2022 Q4 | 1.56 Million USD | -4.4% |
| 2022 Q3 | 1.63 Million USD | -0.97% |
| 2022 FY | 1.56 Million USD | 5293.1% |
| 2022 Q1 | 1.64 Million USD | 5555.17% |
| 2021 Q2 | 198 Thousand USD | -29.03% |
| 2021 FY | 29 Thousand USD | -91.92% |
| 2021 Q1 | 279 Thousand USD | -22.28% |
| 2021 Q4 | 29 Thousand USD | -74.78% |
| 2021 Q3 | 115 Thousand USD | -41.92% |
| 2020 FY | 359 Thousand USD | -45.77% |
| 2020 Q4 | 359 Thousand USD | -18.04% |
| 2020 Q1 | 588 Thousand USD | -11.18% |
| 2020 Q2 | 514 Thousand USD | -12.59% |
| 2020 Q3 | 438 Thousand USD | -14.79% |
| 2019 Q2 | 801 Thousand USD | -7.83% |
| 2019 Q4 | 662 Thousand USD | -9.69% |
| 2019 Q3 | 733 Thousand USD | -8.49% |
| 2019 Q1 | 869 Thousand USD | 0.0% |
| 2019 FY | 662 Thousand USD | 0.0% |
| 2018 Q1 | 3.72 Million USD | 7.84% |
| 2018 FY | - USD | -100.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | -100.0% |
| 2017 Q4 | 3.45 Million USD | 8.49% |
| 2017 Q3 | 3.18 Million USD | 4.26% |
| 2017 Q2 | 3.05 Million USD | -17.85% |
| 2017 Q1 | 3.71 Million USD | 13.56% |
| 2017 FY | 3.45 Million USD | 5.53% |
| 2016 Q1 | 3.13 Million USD | 45.94% |
| 2016 Q4 | 3.26 Million USD | 15.69% |
| 2016 Q3 | 2.82 Million USD | 18.61% |
| 2016 Q2 | 2.38 Million USD | -24.11% |
| 2016 FY | 3.26 Million USD | 51.96% |
| 2015 Q1 | 1.74 Million USD | 10.96% |
| 2015 Q2 | 1.67 Million USD | -4.01% |
| 2015 Q3 | 1.91 Million USD | 14.4% |
| 2015 Q4 | 2.15 Million USD | 12.59% |
| 2015 FY | 2.15 Million USD | 37.18% |
| 2014 Q1 | 285.12 Thousand USD | 2.29% |
| 2014 Q2 | 611.76 Thousand USD | 114.56% |
| 2014 FY | 1.56 Million USD | 462.66% |
| 2014 Q4 | 1.56 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 278.74 Thousand USD | 0.0% |
| 2013 Q3 | 278.74 Thousand USD | 0.0% |
| 2013 FY | 278.74 Thousand USD | 552.04% |
| 2012 FY | 42.75 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | 96.551% |
| Dynavax Technologies Corporation | 256.91 Million USD | 99.51% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 96.966% |
| Perrigo Company plc | 4.07 Billion USD | 99.969% |
| Illumina, Inc. | 2.26 Billion USD | 99.944% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.996% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -26.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.987% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.991% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.275% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.953% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 95.332% |
| Waters Corporation | 2.35 Billion USD | 99.947% |
| Biogen Inc. | 7.33 Billion USD | 99.983% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 96.693% |
| Evolus, Inc. | 126.54 Million USD | 99.004% |
| Adicet Bio, Inc. | 17.7 Million USD | 92.883% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 97.081% |
| bluebird bio, Inc. | 330.32 Million USD | 99.619% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.767% |
| FibroGen, Inc. | 170.45 Million USD | 99.261% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.954% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 93.967% |
| Homology Medicines, Inc. | 44.05 Million USD | 97.14% |
| Geron Corporation | 85.89 Million USD | 98.533% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.947% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 99.717% |
| Myriad Genetics, Inc. | 145 Million USD | 99.131% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 98.908% |
| Zoetis Inc. | 6.8 Billion USD | 99.981% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 71.377% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.942% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.889% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.844% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 96.531% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.913% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 97.823% |
| Verastem, Inc. | 41.55 Million USD | 96.968% |
| Nektar Therapeutics | 230.4 Million USD | 99.453% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 99.324% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 59.011% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.91% |
| OPKO Health, Inc. | 326.56 Million USD | 99.614% |
| Exelixis, Inc. | 189.94 Million USD | 99.337% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.706% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -734.437% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 99.09% |
| Imunon, Inc. | 1.13 Million USD | -10.595% |
| Blueprint Medicines Corporation | 774.12 Million USD | 99.837% |
| Insmed Incorporated | 1.2 Billion USD | 99.895% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.916% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 97.789% |
| TG Therapeutics, Inc. | 110.79 Million USD | 98.863% |
| Incyte Corporation | 38.28 Million USD | 96.709% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 99.856% |